TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03497520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: asymmetric spinal stabilization exercise
Description: The patients were educated to strengthening weakness side of spinal muscle, as asymmetric spinal stabilization exercise(ASSE)~* before teach ASSE, the investigators will evaluate Cobb angle, Apical vertebral rotation in Adam's test, surface EMG, Scoliosis Research Society-22(SRS-22) quastionnaire for evaluation of scoliosis severity~* after perform ASSE, the investigators will evaluate Cobb angle, Apical vertebral rotation in Adam's test, surface EMG, Scoliosis Research Society-22(SRS-22) quastionnaire for evaluation of scoliosis severity
Study: NCT03178318

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound
Description: ultrasound of the neck to identify the position of upper and lower border of the cricothyroid membrane.
Study: NCT02146300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1. session birch pollen nasal exposure 2. session xylometazoline nasal exposure
Description: Aquagen SQ 10 000 SQ/ml nasal exposure Xylometazoline 1 mg/ml nasal exposure
Study: NCT01314638

Intervention type: OTHER
Intervention: Workshop balances
Description: one workshop per week for 20 weeks. Evaluation before and after.
Study: NCT03925519

Intervention type: OTHER
Intervention: Supervised aerobic exercise
Study: NCT04543942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol will be administered by IV infusion (60mg%).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol will be administered by IV infusion (60mg%).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline is administered as the placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline is administered as the placebo
Study: NCT02720978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Description: Intravenous oxytocin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal prostaglandin
Description: Vaginal prostaglandin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery.
Study: NCT03404440

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: L.Reuteri

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: L.Reuteri
Study: NCT03239353

Intervention type: DRUG
Group type: OTHER
Intervention: Entecavir
Description: Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir
Description: Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.
Study: NCT02570971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Study: NCT00926978

Intervention type: RADIATION
Group type: OTHER
Intervention: Radioactive Iodine 124
Description: After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is \< 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131.
Study: NCT03437902

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rutin in combination with Vitamin C
Description: Rutin and Vitamin C will be supplied as tablets containing 60 mg Rutin and 160 mg Vitamin C. The use of Rutin and Vitamin C will be under the trade name of RUTA C 60 ® manufactured by KAHIRA PHARM.\& CHEM. IND. Company

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C will be supplied as capsules containing500 mg of Vitamin C. The use of Vitamin C will be under the trade name of C-Retard ® manufactured by HIKMA Quality Company.
Study: NCT02080117

Intervention type: PROCEDURE
Intervention: kidney transplantation, living or deceased donor
Study: NCT03130699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dulce Digital
Description: One-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dulce Digital-Me (Automated Delivery)
Description: Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dulce Digital-Me (Medical Assistant)
Description: Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
Study: NCT00859469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/m2 IV infusion for 2 hours
Study: NCT02905591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Conformal radiation administered daily, Monday through Friday Total dose is 60 Gray (Gy) and is delivered in 2 Gy fractions. One fraction is delivered daily for a total of 30 fractions in 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously (IV) Given the same day as carboplatin, but given before the carboplatin is administered~* the dose is 45 mg/m2 (standard dose)~* Administered weekly~* 6 to 7 weeks of therapy, depending on when radiation starts~* Standardized dose reductions are used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously (IV) GIven the same day as paclitaxel, immediately after the paclitaxel infusion is done.~* Prescribed at area-under-the-curve (AUC) = 2 using the Cockroft-Gault formula (standard)~* Administered weekly~* 6 to 7 weeks of therapy, depending on when radiation starts~* Standard dose reductions are used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Administered intravenously~* 75 grams per infusion; each infusion is about 2 hours~* 3 infusion per calendar week~* The infusion is actively running for at least 20 minutes when radiation begins~* May be given while chemotherapy is delayed due to low counts~* Dose reductions are not used~* Given for 6 to 7 weeks, depending on when radiation starts
Study: NCT00791765

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept for subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept for subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for subcutaneous injection.
Study: NCT02754648

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic ovarian endometriotic cyst

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic ovarian endometriotic cyst

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic ovarian endometriotic cyst
Study: NCT01351285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: up-and-down method to find out effective concentration of remifentanil for preventing cough
Description: During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: up-and-down method to find out effective concentration of remifentanil for preventing cough
Description: During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: up-and-down method to find out effective concentration of remifentanil for preventing cough
Description: During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
Study: NCT04219033

Intervention type: OTHER
Intervention: EEG(Electroencephalogram) change
Description: patients are found to have characteristic EEG change

Intervention type: OTHER
Intervention: EEG(Electroencephalogram) change
Description: patients are found to have characteristic EEG change
Study: NCT02812706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution Route of administration: intravenous
Study: NCT04370392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraperitoneal local anaesthetic instillation
Description: intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25) through the trocar at the subdiaphragmatic space in Trendelenburg's position for 5 min with intravenous infusion of 50 ml normal saline over 10 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraperitoneal local anaesthetic instillation
Description: intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25) through the trocar at the subdiaphragmatic space in Trendelenburg's position for 5 min with intravenous infusion of 50 ml normal saline over 10 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraperitoneal local anaesthetic instillation
Description: intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25) through the trocar at the subdiaphragmatic space in Trendelenburg's position for 5 min with intravenous infusion of 50 ml normal saline over 10 minutes.
Study: NCT04028128

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa group
Description: Athletes performed a training program and consumed 5 g of cocoa (425 mg of flavonoids) mixed with semi-skimmed fat milk, daily for 10 weeks.
Study: NCT01592032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin antimicrobial-lock solution
Description: Randomization of 5 patients into vancomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teicoplanin antimicrobial-lock solution
Description: Randomization of 5 patients into teicoplanin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
Study: NCT04028128

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The athletes performed the same training program of the cocoa group and they took for 10 weeks 5 g of maltodextrin mixed with semi-skimmed fat milk.
Study: NCT04503889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transauricular electrical vagal nerve stimulation
Description: transauricular electrical vagal nerve stimulation will be applied to the cymba conchae of both ears using ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany) with currency intensity of max 10 mA and current frequency 2/100 Hz.
Study: NCT01592032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid antimicrobial-lock solution
Description: Randomization of 5 patients into linezolid antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin antimicrobial-lock solution
Description: Randomization of 5 patients into daptomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline antimicrobial-lock solution
Description: Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
Study: NCT02733900

Intervention type: PROCEDURE
Group type: OTHER
Intervention: femoral head removal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femoral head removal
Study: NCT04503889

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transauricular electrical vagal nerve stimulation
Description: transauricular electrical vagal nerve stimulation will be applied to the cymba conchae of both ears using ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany) with currency intensity of max 10 mA and current frequency 2/100 Hz.
Study: NCT02248870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is added to Bupivacaine with Adrenaline for perineural injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is added as a placebo to Bupivacaine with adrenaline for perineural injection
Study: NCT04484285

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Vagal Nerve Stimulation (tVNS)
Description: vagal nerve stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Vagal Nerve Stimulation (tVNS)
Description: vagal nerve stimulation
Study: NCT01682460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refresh Tears Lubricant Eye Drops (Allergan)
Description: Eye drops QID for 1 month
Study: NCT03347500

Intervention type: OTHER
Intervention: use of patient-derived biological samples
Description: We will use biological samples that are routinely collected as waste material from patients undergoing prosthetic surgery at IRCCS Istituto Ortopedico Galeazzi. Peripheral blood will be also collected from patients during the pre-surgery visit and during the post-surgery hospitalization coinciding with routine blood sample collection.

Intervention type: OTHER
Intervention: use of patient-derived biological samples
Description: We will use biological samples that are routinely collected as waste material from patients undergoing prosthetic surgery at IRCCS Istituto Ortopedico Galeazzi. Peripheral blood will be also collected from patients during the pre-surgery visit and during the post-surgery hospitalization coinciding with routine blood sample collection.
Study: NCT02370212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High intensity interval training
Study: NCT01820728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-3801 Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-F®
Study: NCT05131295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone
Description: Dapsone is a drug that has been used clinically for several decades due to its anti-infective effect. It has an anti-inflammatory effect due to its inhibitory action on neutrophils. Neuroprotective effects have been found experimentally with the use of dapsone, predominantly through its glutamate receptors antagonistic effect; these are the main receptors involved in neuronal excitotoxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aluminum Hydroxide Gel
Description: Aluminum Hydroxide Gel is an antacid that works quickly to lower the acid in the stomach
Study: NCT04525404

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI (heart, brain, lungs, liver)
Description: MRI (heart, brain, lungs, liver)

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI (heart, brain, lungs, liver)
Description: MRI (heart, brain, lungs, liver)

Intervention type: DIAGNOSTIC_TEST
Intervention: Bloodwork
Description: Serum biomarkers to assess systemic inflammation, renal function, cardiac injury, liver injury and steatosis, ACE-2 related peptides, cytokines, Activin A and autoantibodies to cardiac antigens, humoral cell RNA

Intervention type: DIAGNOSTIC_TEST
Intervention: Bloodwork
Description: Serum biomarkers to assess systemic inflammation, renal function, cardiac injury, liver injury and steatosis, ACE-2 related peptides, cytokines, Activin A and autoantibodies to cardiac antigens, humoral cell RNA

Intervention type: OTHER
Intervention: Cognitive testing
Description: NIH toolbox Cognitive Measures

Intervention type: OTHER
Intervention: Cognitive testing
Description: NIH toolbox Cognitive Measures

Intervention type: OTHER
Intervention: Olfaction testing
Description: Brief Smell Identification Test (BSIT)

Intervention type: OTHER
Intervention: Olfaction testing
Description: Brief Smell Identification Test (BSIT)

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Spirometry to evaluate forced expiratory volume in 1 second and forced vital capacity

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Spirometry to evaluate forced expiratory volume in 1 second and forced vital capacity

Intervention type: OTHER
Intervention: Walk Test
Description: Walk test to record overall distance walked in 6 minutes and time taken to walk the first 25 feet

Intervention type: OTHER
Intervention: Walk Test
Description: Walk test to record overall distance walked in 6 minutes and time taken to walk the first 25 feet
Study: NCT03312556

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure (CPAP)
Description: Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill or patch. Single dose
Study: NCT02420002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of MEOPA during suturing
Description: Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing of a wound.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Hypnosis during suturing
Description: Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing of the wound will therefore take place under hypnosis (and MEOPA if necessary).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stitch removal
Description: 6 to 15 days after the initial suturing, stitches will be removed according to usual procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stitch removal
Description: 6 to 15 days after the initial suturing, stitches will be removed according to usual procedures.
Study: NCT02345031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AUT00063
Description: 600 mg, orally, once a day, for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally, once a day, for 4 weeks